The optimal management of anti-thrombotic therapy after valve replacement: Certainties and uncertainties

European Heart Journal

Volumn 35, Issue 42, 2014, Pages 2942-2949a

  Iung, Bernard ^a,b   Rodes Cabau, Josep ^c  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

Anticoagulant therapy; Antiplatelet drugs; Bioprosthesis; Mechanical prosthesis; Transcatheter aortic valve implantation; Valve prosthesis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; APIXABAN; CLOPIDOGREL; DABIGATRAN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; THIENOPYRIDINE DERIVATIVE; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ATHEROSCLEROTIC PLAQUE; BLEEDING; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; CORONARY STENTING; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART VALVE BIOPROSTHESIS; HEART VALVE REPLACEMENT; HEPARINIZATION; HIGH RISK PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; LONG TERM CARE; MECHANICAL HEART VALVE; MITRAL VALVE PROSTHESIS; PERIPHERAL VASCULAR DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); POSTOPERATIVE CARE; PRACTICE GUIDELINE; PROSTHESIS THROMBOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTENOSIS; REVIEW; SELF MONITORING; SUDDEN CARDIAC DEATH; THROMBOEMBOLISM; THROMBOSIS; TRANSCATHETER AORTIC VALVE IMPLANTATION; UNCERTAINTY; VENOUS THROMBOEMBOLISM; BIOPROSTHESIS; CHEMICALLY INDUCED; HEART VALVE PROSTHESIS; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROCEDURES; STENT;

ACUTE CORONARY SYNDROME; ANTICOAGULANTS; BIOPROSTHESIS; HEART VALVE PROSTHESIS; HEART VALVE PROSTHESIS IMPLANTATION; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; LONG-TERM CARE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STENTS; THROMBOEMBOLISM; TRANSCATHETER AORTIC VALVE REPLACEMENT;

EID: 84912123414     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu365     Document Type: Review

References (65)

1. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994;89: 635-641.
2. Mok CK, Boey J, Wang R, Chan TK, Cheung KL, Lee PK, Chow J, Ng RP, Tse TF. War-farin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial. Circulation 1985;72:1059-1063.
3. Saour JN, Sieck JO, Mamo LA, Gallus AS. Trial of different intensities of anticoagula-tion in patients with prosthetic heart valves. N Engl J Med 1990;322:428-432.
4. Altman R, Rouvier J, Gurfinkel E, D'Ortencio O, Manzanel R, de La Fuente L, Favaloro RG. Comparisonoftwo levelsofanticoagulanttherapyinpatients with substitute heart valves. J Thorac Cardiovasc Surg 1991;101:427-431.
5. Acar J, Iung B, Boissel JP, Samama MM, Michel PL, Teppe JP, Pony JC, Breton HL, Thomas D, Isnard R, de Gevigney G, Viguier E, Sfihi A, Hanania G, Ghannem M, Mirode A, Nemoz C. AREVA: multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. Circulation 1996;94:2107-2112.
6. Hering D, Piper C, Bergemann R, Hillenbach C, Dahm M, Huth C, Horstkotte D. Thromboembolic and bleeding complications following St. Jude Medical valve replacement: results of the German experience with low-intensity anticoagulation study. Chest 2005;127:53-59.
7. Koertke H, Zittermann A, Tenderich G, Wagner O, El-Arousy M, Krian A, Ennker J, Taborski U, Klovekorn WP, Moosdorf R, Saggau W, Koerfer R. Low-dose oral antic-oagulation in patients with mechanical heart valve prostheses: final report from the early self-management anticoagulation trial II. Eur Heart J 2007;28:2479-2484.
8. Torella M, Torella D, Chiodini P, Franciulli M, Romano G, De Santo L, De Feo M, Amarelli C, Sasso FC, Salvatore T, Ellison GM, Indolfi C, Cotrufo M, Nappi G. LOWERing the INtensity of oral anticoaGulant Therapy in patients with bileaflet mechanical aortic valve replacement: results from the 'LOWERING-IT' trial. Am Heart J 2010;160:171-178.
9. Puskas J, Gerdisch M, Nichols D, Quinn R, Anderson C, Rhenman B, Fermin L, McGrath M, Kong B, Hughes C, Sethi G, Wait M, Martin T, Graeve A. Reduced antic-oagulation after mechanical aortic valve replacement: interim results from the prospective randomized on-X valve anticoagulation clinical trial randomized Food and Drug Administration investigational device exemption trial. J Thorac Cardiovasc Surg 2014;147:1202-1210.
10. Turpie AG, Gent M, Laupacis A, Latour Y, Gunstensen J, Basile F, Klimek M, Hirsh J. A comparisonofaspirin with placeboinpatients treated with warfarin after heart-valve replacement. N Engl J Med 1993;329:524-529.
11. Altman R, Rouvier J, Gurfinkel E, Scazziota A, Turpie AG. Comparison of high-dose with low-dose aspirin in patients with mechanical heart valve replacement treated with oral anticoagulant. Circulation 1996;94:2113-2116.
12. Meschengieser SS, Fondevila CG, Frontroth J, Santarelli MT, Lazzari MA. Low-intensity oral anticoagulation plus low-dose aspirin versus high-intensity oral antic-oagulation alone: a randomized trial in patients with mechanical prosthetic heart valves. J Thorac Cardiovasc Surg 1997;113:910-916.
13. Little SH, Massel DR. Antiplatelet and anticoagulation for patients with prosthetic heart valves. Cochrane Database Syst Rev 2003;7:CD003464.
14. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H, Borger MA, Carrel TP, De Bonis M, Evangelista A, Falk V, Iung B, Lancellotti P, Pierard L, Price S, Schafers HJ, Schuler G, Stepinska J, Swedberg K, Takkenberg J, Von Oppell UO, Windecker S, Zamorano JL, Zembala M, Bax JJ, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Von Segesser L, Badano LP, Bunc M, Claeys MJ, Drinkovic N, Filippatos G, Habib G, Kappetein AP, Kassab R, Lip GY, Moat N, Nickenig G, Otto CM, Pepper J, Piazza N, Pieper PG, Rosenhek R, Shuka N, Schwammenthal E, Schwitter J, Mas PT, Trindade PT, Walther T. Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2012;33:2451-2496.
15. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, O'Gara PT, Ruiz CE, Skubas NJ, Sorajja P, Sundt TM 3rd, Thomas JD. 2014 AHA/ACC Guideline for the Management of Patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129:e521-e643.
16. Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e576S-e600S.
17. Butchart EG, Payne N, Li HH, Buchan K, Mandana K, Grunkemeier GL. Better antic-oagulation control improves survival after valve replacement. JThorac Cardiovasc Surg 2002;123:715-723.
18. Witt DM, Sadler MA, Shanahan RL, Mazzoli G, Tillman DJ. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest 2005;127:1515-1522.
19. Heneghan C, Ward A, Perera R, Bankhead C, Fuller A, Stevens R, Bradford K, Tyndel S, Alonso-Coello P, Ansell J, Beyth R, Bernardo A, Christensen TD, Cromheecke ME, Edson RG, Fitzmaurice D, Gadisseur AP, Garcia-Alamino JM, Gardiner C, Hasenkam JM, Jacobson A, Kaatz S, Kamali F, Khan TI, Knight E, Kortke H, Levi M, Matchar D, Menendez-Jandula B, Rakovac I, Schaefer C, Siebenhofer A, Souto JC, Sunderji R, Gin K, Shalansky K, Voller H, Wagner O, Zittermann A. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet 2012;379:322-334.
20. Sun JC, Davidson MJ, Lamy A, Eikelboom JW. Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. Lancet 2009;374:565-576.
21. Bussey HI, Bussey M, Bussey-Smith KL, Frei CR. Evaluation of warfarin management with international normalized ratio self-testing and online remote monitoring and management plus low-dose vitamin K with genomic considerations: a pilot study. Pharmacotherapy 2013;33:1136-1146.
22. Pernod G, Godier A, Gozalo C, Tremey B, Sie P. French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding). Thromb Res 2010;126:e167-e174.
23. Hansen ML, Sørensen R, Clausen MT, Fog-Petersen ML, Raunsø J, Gadsbøll N, Gislason GH, Folke F, Andersen SS, Schramm TK, Abildstrøm SZ, Poulsen HE, Køber L, Torp-Pedersen C. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010;170:1433-1441.
24. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, Adriaenssens T, Vrolix M, Heestermans AA, Vis MM, Tijsen JG, van 't Hof AW, ten Berg JM, WOEST Study Investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013; 381:1107-1115.
25. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, Khder Y, Lobmeyer MT, Maas H, Voigt JU, Simoons ML, Van deWerf F. Dabigatran versus warfarininpatients with mechanical heart valves. N Engl J Med 2013;369:1206-1214.
26. Iung B, Vahanian A. Lessons from the RE-ALIGN trial. Arch Cardiovasc Dis 2014;107: 277-279.
27. Butchart EG, Lewis PA, Bethel JA, Breckenridge IM. Adjusting anticoagulation to prosthesis thrombogenicity and patient risk factors. Recommendations for the Medtronic Hall valve. Circulation 1991;84:III61-III69.
28. Laplace G, Lafitte S, Labeque JN, Perron JM, Baudet E, Deville C, Roques X, Roudaut R. Clinical significance of early thrombosis after prosthetic mitral valve re-placement:apostoperative monocentric studyof 680 patients. JAm Coll Cardiol 2004; 43:1283-1290.
29. Butchart EG, Gohlke-Barwolf C, Antunes MJ, Tornos P, De Caterina R, Cormier B, Prendergast B, Iung B, Bjornstad H, Leport C, Hall RJ, Vahanian A. Recommendations for the management of patients after heart valve surgery. Eur Heart J 2005;26: 2463-2471.
30. Kulik A, Rubens FD, Wells PS, Kearon C, Mesana TG, van Berkom J, Lam BK. Early postoperative anticoagulation after mechanical valve replacement: a systematic review. Ann Thorac Surg 2006;81:770-781.
31. Laffort P, Roudaut R, Roques X, Lafitte S, Deville C, Bonnet J, Baudet E. Early and long-term (one-year) effects of the association of aspirin and oral anticoagulant on thrombi and morbidity after replacement of the mitral valve with the St. Jude medical prosthesis: a clinical and transesophageal echocardiographic study. J Am Coll Cardiol 2000;35:739-746.
32. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med 1997;336:1506-1511.
33. Heras M, Chesebro JH, Fuster V, Penny WJ, Grill DE, Bailey KR, Danielson GK, Orszulak TA, Pluth JR, Puga FJ et al. High risk of thromboemboli early after biopros-thetic cardiac valve replacement. J Am Coll Cardiol 1995;25:1111-1119.
34. Russo A, Grigioni F, Avierinos JF, Freeman WK, Suri R, Michelena H, Brown R, Sundt TM, Enriquez-Sarano M. Thromboembolic complications after surgical correction of mitral regurgitation incidence, predictors, and clinical implications. J Am Coll Cardiol 2008;51:1203-1211.
35. Colli A, Verhoye JP, Leguerrier A, Gherli T. Anticoagulationorantiplatelet therapy of bioprosthetic heart valves recipients: an unresolved issue. Eur J Cardiothorac Surg 2007;31:573-577.
36. Nowell J, Wilton E, Markus H, Jahangiri M. Antithrombotic therapy following bio-prosthetic aortic valve replacement. Eur J Cardiothorac Surg 2007;31:578-585.
37. Gherli T, Colli A, Fragnito C, Nicolini F, Borrello B, Saccani S, D'Amico R, Beghi C. Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study. Circulation 2004;110:496-500.
38. Aramendi JI, Mestres CA. Antithrombotic therapy after bioprosthetic aortic valve replacement. Eur J Cardiothorac Surg 2008;33:529-530.
39. Colli A, Verhoye JP, Heijmen R, Strauch JT, Hyde JA, Pagano D, Antunes M, Koertke H, Ohri SK, Bail DH, Leprince P, Van Straten BH, Gherli T. Antithrombotic therapy after bioprosthetic aortic valve replacement: ACTION Registry survey results. Eur J Cardiothorac Surg 2008;33:531-536.
40. Vaughan P, Waterworth PD. An audit of anticoagulation practice among UK cardio-thoracic consultant surgeons following valve replacement/repair. J Heart Valve Dis 2005;14:576-582.
41. Brennan JM, Alexander KP, Wallace A, Hodges AB, Laschinger JC, Jones KW, O'Brien S, Webb LE, Dokholyan RS, Peterson ED. Patterns of anticoagulation following bioprosthetic valve implantation: observations from ANSWER. J Heart Valve Dis 2012; 21: 78-87.
42. Brennan JM, Edwards FH, Zhao Y, O'Brien S, Booth ME, Dokholyan RS, Douglas PS, Peterson ED. Early anticoagulation of bioprosthetic aortic valves in older patients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database. J Am Coll Cardiol 2012;60:971-977.
43. Merie C, Kober L, Skov Olsen P, Andersson C, Gislason G, Skov Jensen J, Torp-Pedersen C. Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. JAMA 2012;308:2118-2125.
44. Holmes DR Jr, Mack MJ, Kaul S, Agnihotri A, Alexander KP, Bailey SR, Calhoon JH, Carabello BA, Desai MY, Edwards FH, Francis GS, Gardner TJ, Kappetein AP, Linderbaum JA, Mukherjee C, Mukherjee D, Otto CM, Ruiz CE, Sacco RL, Smith D, Thomas JD. 2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. J Am Coll Cardiol 2012;59:1200-1254.
45. Webb J, Rodés-Cabau J, Fremes S, Pibarot P, Ruel M, Ibrahim R, Welsh R, Feindel C, Lichtenstein S. Transcatheter aortic valve implantation: a Canadian Cardiovascular Society position statement. Can J Cardiol 2012;28:520-528.
46. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Williams M, Dewey T, Kapadia S, Babaliaros V, Thourani VH, Corso P, Pichard AD, Bavaria JE, Herrmann HC, Akin JJ, Anderson WN, Wang D, Pocock SJ. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011;364:2187-2198.
47. Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, Gleason TG, Buchbinder M, Hermiller J Jr, Kleiman NS, Chetcuti S, Heiser J, Merhi W, Zorn G, Tadros P, Robinson N, Petrossian G, Hughes GC, Harrison JK, Conte J, Maini B, Mumtaz M, Chenoweth S, Oh JK. Transcatheter aortic-valve replacement with aself-expanding prosthesis. N Engl J Med 2014;370:1790-1798.
48. Nombela-Franco L, Webb JG, de Jaegere PP, Toggweiler S, Nuis RJ, Dager AE, Amat-Santos IJ, Cheung A, Ye J, Binder RK, van der Boon RM, Van Mieghem N, Benitez LM, Pérez S, Lopez J, San Roman JA, Doyle D, Delarochellière R, Urena M, Leipsic J, Dumont E, Rodés-Cabau J. Timing, predictive factors, and prognostic value ofcerebrovascular events in a large cohort of patients undergoing trans-catheter aortic valve implantation. Circulation 2012;126:3041-3053.
49. Rodés-Cabau J, Dauerman HL, Cohen MG, Mehran R, Small EM, Smyth SS, Costa MA, Mega JL, O'Donoghue ML, Ohman EM, Becker RC. Antithrombotictreat-ment in transcatheter aortic valve implantation: insights for cerebrovascular and bleeding events. J Am Coll Cardiol 2013;62:2349-2359.
50. Makkar RR, Fontana GP, Jilaihawi H, Kapadia S, Pichard AD, Douglas PS, Thourani VH, Babaliaros VC, Webb JG, Herrmann HC, Bavaria JE, Kodali S, Brown DL, Bowers B, Dewey TM, Svensson LG, Tuzcu M, Moses JW, Williams MR, Siegel RJ, Akin JJ, Anderson WN, Pocock S, Smith CR, Leon MB. Trans-catheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl JMed 2012;366:1696-1704.
51. Mok M, Urena M, Nombela-Franco L, Ribeiro HB, Allende R, Delarochellière R, Doyle D, Dumont E, Cô té M, Rodés-Cabau J. Clinical and prognostic implications of existing and new-onset atrial fibrillation in patients undergoing transcatheter aortic valve implantation. J Thromb Thrombolysis 2013;35:450-455.
52. Latib A, Messika-Zeitoun D, Maisano F, Himbert D, Agricola E, Brochet E, Alfieri O, Colombo A, Vahanian A. Reversible Edwards Sapien XT dysfunction due to prosthesis thrombosis presenting as early structural deterioration. J Am Coll Cardiol 2013;61:787-789.
53. Cota L, Stabile E, Agrusta M, Sorropago G, Pucciarelli A, Ambrosini V, Mottola G, Esposito G, Rubino P. Bioprostheses 'thrombosis' after transcatheter aortic valve replacement. J Am Coll Cardiol 2013;61:789-791.
54. Trepels T, Martens S, Doss M, Fichtlscherer S, Schächinger V. Thrombotic restenosis after minimally invasive implantation of aortic valve stent. Circulation 2009;120: e23-e24.
55. Kefer J, Astarci P, Renkin J, Glineur D, Pierard S, Seldrum S, Vanoverschelde JL. Thrombotic aortic restenosis after transapical Sapien valve implantation. Circ Cardi-ovasc Interv 2010;3:289-292.
56. Tay ELW, Gurvitch R, Wijeysinghe N, Nietlispach F, Wood D, Allard M, Munt B, Cheung A, Webb JG. Valve thrombosis after transcatheter heart valve implantation. Eurointervention 2011;7:170-171.
57. Pache G, Blanke P, Zeh W, Jander N. Cusp thrombosis after transcatheter aortic valve replacement detected by computed tomography and echocardiography. Eur Heart J 2013;34:3546.
58. Lancellotti P, Radermecker MA, Weisz SH, Legrand V. Subacute transcatheter Core Valve thrombotic obstruction. Circ Cardiovasc Interv 2013;6:e32-e33.
59. Orbach A, Karkabi B, Shiran A. Reversible restenosis after transcatheter aortic valve implantation. Eur Heart J Cardiovasc Imaging 2014;15:350.
60. Pergolini A, Pino PG, Zampi G, Polizzi V, Musumeci F. Thrombotic aortic restenosis after transapical Sapien valve implantation. J Card Surg 2014;29:204-208.
61. de Brito FS Jr, Caixeta AM, Vieira ML, Nomura C, Figueiredo GL, Perin M, Marin-Neto JA. Pseudo early degeneration of a transcatheter aortic valve prosthesis due to thrombosis. Euro Intervention 2014;pii: 20130812-04. [Epub ahead of print].
62. Ussia GP, Scarabelli M, Mulè M, Barbanti M, Sarkar K, Cammalleri V, Immè S, Aruta P, Pistritto AM, Gulino S, Deste W, Capodanno D, Tamburino C. Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation. Am J Cardiol 2011;108:1772-1776.
63. Durand E, Blanchard D, Chassaing S, Gilard M, Laskar M, Borz B, Lafont A, Barbey C, Godin M, Tron C, Zegdi R, Chatel D, Le Page O, Litzler PY, Bessou JP, Danchin N, Cribier A, Eltchaninoff H. Comparison of two antiplatelet therapy strategies in patients undergoing transcatheter aortic valve implantation. Am J Cardiol 2014; 113:355-360.
64. Stabile E, Pucciarelli A, Cota L, Sorropago G, Tesorio T, Salemme L, Popusoi G, Ambrosini V, Cioppa A, Agrusta M, Catapano D, Moscariello C, Trimarco B, Esposito G, Rubino P. SAT-TAVI (single antiplatelet therapy for TAVI) study: a pilot randomized study comparing double to single antiplatelet therapy for trans-catheter aortic valve implantation. Int J Cardiol 2014;174:624-627.
65. Zeymer U, Zahn R, Gerckens U, Richardt G, Figulla H-R, Senges J. Antithrombotic therapy after transfemoral aortic valve implantation (TAVI). Potential hazard of triple-therapy (abstr). Eur Heart J 2011;32(suppl.):900.